Abstract
Objective. To investigate the paper radiofrequency ablation (RFA) CT-guided feasibility of hepatocellular carcinoma (primary liver cancer) treatment, safety, and clinical efficacy of the use of deep learning algorithms. Method. A total of 47 cases of primary liver cancer patients were included: 21 cases of CT-guided liver lesions in line with RFA (C-CT group) and, in the same period, 26 cases of spiral CT-guided liver lesions in line with RFA (S-CT group). Two groups of patients were recorded immediately after the total operation time and ablation time, the acceptable radiation dose was observed in the incidence of postoperative complications of 7d, and the postoperative hospital stay was recorded to evaluate the efficacy of the treatment of lesions in 1, 3, and 6 months after RFA. Results. All 47 patients were successful; two technical success rates were 100%. There was a significant difference ( P < 0.05) in the total operation time groups, ablation time, and acceptable radiation dose. And there was no significant difference ( P < 0.05) in postoperative complications of 7d groups, postoperative hospital stay, and local disease control. There was a significant difference ( P < 0.05) in the S-CT group, seven ablation residual or recurrent lesions during the follow-up ratio of 26.9%, and C-CT groups compared with only 14.3%. Conclusion. CT-guided RFA treatment of primary liver cancer patients is safe, effective, and superior to the conventional spiral CT-guided ablation lesion site-specific terms.
Highlights
Surgical resection of primary liver cancer and liver transplantation is the preferred treatment, but more than 80% of patients at the time of diagnosis have lost the opportunity for surgery, and the 5-year recurrence rate is about 40% to 70%
Except for the slightly younger age of the patients in the C-CT group, there was no significant difference in the general data between the two groups, and they were comparable [2]. e Radiofrequency ablation (RFA) treatment of all 47 lesions was performed by the same team using a unified angiography machine (France) and radiofrequency ablation equipment (1500X radio frequency generator and Starburst radiofrequency needle, RITA, USA)
TACE has been used in the treatment of liver cancer at home and abroad for a long time, and its efficacy has been affirmed. It has been found in a large number of clinical practices that TACE does not completely cause tumor necrosis. e complete tumor necrosis rate is only about 20%, which may be related to collateral circulation, multiarterial blood supply, and partial blood supply around the tumor from the portal vein, and incomplete embolization other factors are related; in addition, tumors with poor blood supply have worse efficacy, so local recurrence and progression of tumors will occur after TACE alone, and patients with liver cancer are often accompanied by hepatitis and cirrhosis background
Summary
Surgical resection of primary liver cancer and liver transplantation is the preferred treatment, but more than 80% of patients at the time of diagnosis have lost the opportunity for surgery, and the 5-year recurrence rate is about 40% to 70%. For unresectable primary liver cancer and postoperative recurrence, treatment can be through a variety of interventional transcatheter arterial chemoembolization and physical ablation, etc., and has been widely used in clinical practice. Radiofrequency ablation (RFA) as a minimally invasive method for curative treatment in the field of interventional tumors has been widely carried out. Substantial research and clinical guidelines state that, in patients with small diameter
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
